IRIS
LADETTO, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.903
NA - Nord America 4.617
AS - Asia 3.809
SA - Sud America 855
Continente sconosciuto - Info sul continente non disponibili 301
AF - Africa 146
OC - Oceania 5
Totale 14.636
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.436
RU - Federazione Russa 1.869
SG - Singapore 1.490
IE - Irlanda 1.352
HK - Hong Kong 716
BR - Brasile 660
CN - Cina 612
VN - Vietnam 481
IT - Italia 325
SE - Svezia 319
DE - Germania 278
UA - Ucraina 250
FR - Francia 225
BD - Bangladesh 127
IN - India 90
GB - Regno Unito 82
CA - Canada 78
AR - Argentina 68
FI - Finlandia 65
BJ - Benin 59
MX - Messico 54
ID - Indonesia 52
EC - Ecuador 44
KR - Corea 37
JP - Giappone 35
IQ - Iraq 32
NL - Olanda 29
ZA - Sudafrica 27
PL - Polonia 23
CO - Colombia 22
AT - Austria 19
TR - Turchia 19
CL - Cile 18
PK - Pakistan 16
VE - Venezuela 15
EG - Egitto 14
JM - Giamaica 13
SA - Arabia Saudita 13
UZ - Uzbekistan 13
LT - Lituania 12
ES - Italia 11
PE - Perù 11
PY - Paraguay 11
MA - Marocco 10
TN - Tunisia 10
AE - Emirati Arabi Uniti 9
CZ - Repubblica Ceca 9
IR - Iran 9
KE - Kenya 9
DZ - Algeria 7
PH - Filippine 7
CR - Costa Rica 6
EU - Europa 6
MY - Malesia 6
AU - Australia 5
GR - Grecia 5
TH - Thailandia 5
BO - Bolivia 4
GT - Guatemala 4
KZ - Kazakistan 4
LB - Libano 4
NI - Nicaragua 4
PT - Portogallo 4
RO - Romania 4
SV - El Salvador 4
TT - Trinidad e Tobago 4
AZ - Azerbaigian 3
BB - Barbados 3
BE - Belgio 3
DO - Repubblica Dominicana 3
HN - Honduras 3
JO - Giordania 3
NP - Nepal 3
OM - Oman 3
PS - Palestinian Territory 3
TW - Taiwan 3
XK - ???statistics.table.value.countryCode.XK??? 3
BN - Brunei Darussalam 2
CI - Costa d'Avorio 2
EE - Estonia 2
HR - Croazia 2
KW - Kuwait 2
PA - Panama 2
SI - Slovenia 2
SY - Repubblica araba siriana 2
UY - Uruguay 2
ZM - Zambia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
AO - Angola 1
AW - Aruba 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BS - Bahamas 1
CH - Svizzera 1
DK - Danimarca 1
GA - Gabon 1
GE - Georgia 1
Totale 14.327
Salva come PNG Salva come JPEG
Città #
Dublin 1.348
Hong Kong 714
San Jose 535
Council Bluffs 417
Singapore 408
Ashburn 351
Jacksonville 300
Moscow 255
Wilmington 196
Lauterbourg 192
Princeton 175
Lawrence 174
Ho Chi Minh City 163
San Mateo 145
Los Angeles 137
Chandler 130
Beijing 122
Hanoi 96
Dearborn 84
New York 84
Buffalo 82
Columbus 76
Dallas 75
Santa Clara 72
Cotonou 59
São Paulo 58
Redondo Beach 48
Houston 37
Orem 33
Seoul 33
Frankfurt am Main 29
Novara 29
Tokyo 29
Turin 29
Boardman 28
Piemonte 28
Bremen 26
Milan 26
Rio de Janeiro 25
St Louis 25
Toronto 25
Chennai 24
Falkenstein 24
Ann Arbor 23
Helsinki 23
Tianjin 23
Brooklyn 22
Warsaw 22
Haiphong 21
Montreal 21
Atlanta 20
Denver 20
Chicago 19
Da Nang 19
Fairfield 19
Guangzhou 19
Mexico City 19
Amsterdam 17
Nuremberg 17
Rome 17
Brasília 16
London 16
Phoenix 16
Quito 16
Norwalk 15
Andover 14
Boston 14
Des Moines 14
San Francisco 14
Stockholm 14
Johannesburg 13
Poplar 13
Shanghai 13
Tashkent 13
Woodbridge 13
Baghdad 12
Mumbai 12
Ninh Bình 12
Thái Bình 12
Vienna 12
Curitiba 10
Biên Hòa 9
Brno 9
Guayaquil 9
Hangzhou 9
Munich 9
Porto Alegre 9
Querétaro 9
Seattle 9
Belo Horizonte 8
Hefei 8
Jakarta 8
Las Vegas 8
Lima 8
Manchester 8
Mülheim 8
Philadelphia 8
Salvador 8
Shenzhen 8
Asunción 7
Totale 7.730
Salva come PNG Salva come JPEG
Nome #
Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients 138
The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib 137
STAble: A novel approach to de novo assembly of RNA-seq data and its application in a metabolic model network based metatranscriptomic workflow 137
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 136
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up 136
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the "Fondazione Italiana Linfomi" MCL-0208 trial 134
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study 127
Induction of robust humoral immunity against SARS-CoV-2 after vaccine administration in previously infected haematological cancer patients 122
MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia 122
Applying data warehousing to a phase III clinical trial from the Fondazione Italiana Linfomi (FIL) ensures superior data quality and improved assessment of clinical outcomes 122
ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma 122
Comparison of different DNA extraction methods from peripheral blood cells: advices from the Fondazione Italiana Linfomi - MRD Network. 112
Analysis of the immunoglobulin heavy-chain gene rearrangement providing molecular evidence of second lymphoma in a patient in apparent relapse after autotransplantation 112
Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia 110
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi 109
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage 106
Genetic and phenotypic attributes of splenic marginal zone lymphoma 105
Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies 104
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 100
Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi 99
A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines 99
Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial 99
Changing Trends in B-Cell Non-Hodgkin Lymphoma Treatment: The Role of Novel Monoclonal Antibodies in Clinical Practice 98
THE HOST GENETIC BACKGROUND OF DNA REPAIR MECHANISMS IS AN INDEPENDENT PREDICTOR OF PROGRESSION AND OVERALL SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMA 98
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 97
COMPARISON OF TWO REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION STRATEGIES FOR MINIMAL RESIDUAL DISEASE EVALUATION IN LYMPHOPROLIFERATIVE DISORDERS: CORRELATION BETWEEN IMMUNOGLOBULIN GENE MUTATION LOAD AND REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION PERFORMANCE 97
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartment 97
End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial 95
CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia 95
Allogeneic stem cell transplantation in mantle cell lymphoma in the era of new drugs and CAR-T cell therapy 95
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial 94
A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma 92
High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib 91
A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL) 91
Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: Results of a multicenter study 91
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study 88
The black swan: a case of central nervous system graft-versus-host disease 88
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes 88
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial 86
CAR-T therapy: the role of the hematopoietic stem cell processing laboratory 84
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial 84
A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors 83
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 83
Pharmacotherapy considerations for patients who develop acute kidney injury during cancer therapy 81
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma 81
Hematopoietic Stem Cells (HSC) and Granulocyte Macrophage Progenitors (GMP) are the Oxidative Stress Targets in Low/Intermediate-1 Risk Myelodysplastic Syndromes 80
A Single-Center Pilot Prospective Study of Topical Application of Platelet-Derived Eye Drops for Patients with Ocular Chronic Graft-versus-Host Disease 80
Long-term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients 79
Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 79
Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting) 77
Quality assessment for PCR-based minimal residual disease in Lymphoma: 10 Years of cross-laboratory standardization process within the fondazione italiana linfomi MRD network 77
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study 77
A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients 76
Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 76
Spontaneous splenic rupture during induction therapy in acute myeloid leukemia: An unusual case 76
Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol 75
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial 75
Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial. 74
Next-Generation Therapies in Mantle Cell Lymphoma (MCL): The Evolving Landscape in Treatment of Relapse/Refractory After CAR-T Cells 73
Towards the Definition of a Prognostic Model for Mantle Cell Lymphoma 73
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome 73
Controversies in the treatment of follicular lymphoma 73
Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia 72
Droplet Digital PCR Assay for MYD88L265P 72
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial 72
HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data 71
Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapse/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase 3 trial 71
ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia 70
DEL(13q14) LENGTH MATTERS: AN INTEGRATED ANALYSIS OF GENOMIC, FISH AND CLINICAL DATA IN 169 CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH 13q DELETION ALONE OR NORMAL KARYOTYPE 70
LOW CD49d AND LONG TELOMERE IDENTIFY A CHRONIC LYMPHOCYTIC LEUKEMIA SUBSET WITH HIGHLY FAVOURABLE OUTCOME 70
PCR-detectable non-neoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis, but rare in subjects treated with chemotherapy 70
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network 70
Exposure to obinutuzumab does not affect outcomes of SARS-CoV-2 infection in vaccinated patients with newly diagnosed advanced-stage follicular lymphoma 69
LENALIDOMIDE PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, PREDNISONE AND RITUXIMAB IS SAFE AND EFFECTIVE IN UNTREATED, ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: A PHASE I STUDY BY THE FONDAZIONE ITALIANA LINFOMI 69
Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT 69
Organizational determinants of hospital stay: establishing the basis of a widespread action on more efficient pathways in medical units 68
Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma 68
Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias 68
Stem cell collection and hematological recovery in the Fondazione Italiana Linfomi (FIL) MCL0208 clinical trial 67
Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma 67
Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network 67
Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests 67
Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells 66
The adulthood of MRD detection in MCL 66
Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial 65
Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020 65
EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma 65
Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the FIL MCL0208 trial 65
TWO MAIN GENETIC PATHWAYS LEAD TO THE TRANSFORMATION OF CHRONIC LYMPHOCYTIC LEUKEMIA TO RICHTER SYNDROME 65
High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity 65
Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 65
ESMO consensus conference on Malignant lymphoma: Management of ‘ultra-high-risk’ patients 64
EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Follicular Lymphoma 64
Minimal Residual Disease in Mantle Cell Lymphoma: Methods and Clinical Significance 63
Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders 63
Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL) 63
Erratum to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study 62
Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma 62
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program 62
A SWOT-Consensus for CAR-T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection 61
Totale 8.496
Salva come PNG Salva come JPEG
Categoria #
all - tutte 88.075
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 88.075
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022790 0 20 143 55 47 0 16 16 81 13 172 227
2022/20231.966 179 37 76 18 69 123 41 93 1.251 8 50 21
2023/2024706 17 29 30 12 160 5 176 10 6 16 38 207
2024/20252.233 45 7 41 14 22 217 152 119 805 391 65 355
2025/20267.017 165 212 578 1.113 537 493 1.007 1.127 528 617 407 233
2026/2027763 302 461 0 0 0 0 0 0 0 0 0 0
Totale 14.636